📣 VC round data is live. Check it out!
- Public Comps
- Olympus
Olympus Valuation Multiples
Discover Olympus' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Smith & Nephew, Penumbra, Medpace, Fisher & Paykel and more.
Olympus Overview
About Olympus
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
Founded
1919
HQ

Employees
30.0K
Website
Financials (LTM)
EV
$13B
Valuation Multiples
Start free trialOlympus Financials
Olympus reported last 12-month revenue of $6B and EBITDA of $1B.
In the same LTM period, Olympus generated $4B in gross profit, $1B in EBITDA, and $463M in net income.
Revenue (LTM)
Olympus P&L
In the most recent fiscal year, Olympus reported revenue of $6B and EBITDA of $1B.
Olympus is profitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 23%, and net margin of 12%.
Financial data powered by Morningstar, Inc.
Olympus Stock Performance
Olympus has current market cap of $12B, and enterprise value of $13B.
Market Cap Evolution
Olympus' stock price is $11.31.
Olympus share price increased by 0.9% in the last 30 days, and by 4.8% in the last year.
Olympus has an EPS (earnings per share) of $0.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13B | $12B | -0.3% | 0.9% | 20.6% | 4.8% | $0.67 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOlympus Valuation Multiples
Olympus trades at 2.0x EV/Revenue multiple, and 11.2x EV/EBITDA.
EV / Revenue (LTM)
Olympus Financial Valuation Multiples
As of June 3, 2026, Olympus has market cap of $12B and EV of $13B.
Olympus has a P/E ratio of 26.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Olympus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Olympus Margins & Growth Rates
Olympus grew revenue by 2% but EBITDA decreased by 26% in the last fiscal year.
In the most recent fiscal year, Olympus reported gross margin of 69%, EBITDA margin of 23%, and net margin of 12%.
Olympus Margins
Olympus Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Olympus Operational KPIs
Olympus' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Olympus' Rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Olympus' Rule of X is 28% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Olympus Competitors
Olympus competitors include Smith & Nephew, Penumbra, Medpace, Fisher & Paykel, Align Technology, Solventum, Cooper Companies, Fresenius Medical Care, Zydus Lifesciences and Coloplast.
Most Olympus public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.5x | 2.4x | 9.6x | 9.3x | |||
| 8.6x | 8.2x | 46.5x | 43.8x | |||
| 4.8x | 4.6x | 21.7x | 21.0x | |||
| 9.2x | 9.2x | 26.6x | 26.6x | |||
| 2.7x | 2.7x | 10.2x | 9.8x | |||
| 2.2x | 2.2x | 7.0x | 9.5x | |||
| 3.4x | 3.3x | 10.9x | 10.4x | |||
| 1.0x | 1.0x | 5.2x | 5.3x | |||
This data is available for Pro users. Sign up to see all Olympus competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Olympus
Olympus has acquired 10 companies to date.
Last acquisition by Olympus was on May 25th 2026. Olympus acquired BioProtect for $270M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Olympus
| Description | BioProtect Ltd. is a Herzliya-headquartered medical device company developing biodegradable balloon spacers for radiation therapy protection. Its flagship ProSpace system, CE-marked since 2012, shields rectal tissue during prostate cancer treatments, demonstrating reduced toxicity in clinical studies across 500 patients. The platform extends to applications in breast, lung, and head-neck cancers. Founded in 2004, BioProtect maintains subsidiaries in Germany and the United States, with ongoing FDA trials for U.S. market entry. | TaeWoong Medical USA is the U.S. subsidiary of South Korean firm Taewoong Medical, distributing GI endoscopy stents and accessories from its Irvine, California headquarters since 2010. The portfolio features Niti-S self-expandable metal stents for esophageal, duodenal, and colonic applications, plus biopsy forceps and hemoclips approved by the FDA, serving over 500 hospitals nationwide through partnerships with Olympus America. | Taewoong Medical is a South Korean manufacturer of gastrointestinal stents and endoscopic devices headquartered in Gimpo, Gyeonggi Province, producing over 100 product types including Niti-S esophageal, biliary, and pancreatic stents used in 80 countries. Founded in 2001, the company exports 90 percent of its output to markets in the U.S., Europe, and Asia, holding FDA approval and CE marking for devices like the Easy Guidewire and retrieval forceps. | Odin Vision is a London-headquartered company building AI applications for gastrointestinal endoscopy, including real-time polyp detection and characterization tools. FDA-cleared since 2021, its cloud platform processes videos from Olympus and Pentax scopes, deployed in UK NHS trusts and US clinics to improve adenoma detection rates. | |
| HQ Country | |||||
| HQ City | Tzur Moshe | Seoul | Seoul | London | |
| Deal Date | 25 May 2026 | 24 Jan 2024 | 23 Feb 2023 | 20 Dec 2022 | |
| Valuation | $270M | $370M | $370M | $80M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Olympus acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Olympus
Olympus has invested in 5 companies to date.
Latest investment by Olympus was on August 15th 2024. Olympus invested in Neptune Medical in their $97M Series D round (EV/Revenue multiple available to Pro users).
Latest Investments by Olympus
| Description | Neptune Medical is a California-based medical device company that develops single-use endoluminal tools for gastroenterology procedures. Its GiPathfinder platform enhances visualization and tissue acquisition during endoscopic surgeries, improving diagnostic accuracy in Barrett's esophagus and colorectal applications. | NeuSpera Medical is a U.S.-headquartered bioelectronics company developing wirelessly powered implants for neuromodulation. Its 2mm tibial nerve stimulator treats overactive bladder via external cuff powering, implanted in 30-minute procedures. NeuSpera reports 80% responder rates in EU trials at University College London since 2021 FDA Breakthrough status. | Eximis Surgical is a Louisville-headquartered medtech company founded in 2014 that develops RF-energized cutting wire technology for morcellation. The system deploys wires inside a containment bag to fragment and extract large tissue specimens through minimally invasive laparoscopic incisions, reducing procedure times in gynecological and urological surgeries. Its BAGEL device received FDA 510(k) clearance in 2020 for use in hysterectomies and myomectomies. | Virgo is a Boston-based provider of video capture, management, and AI analytics platforms tailored for endoscopy procedures. The firm partners with leading medical institutions such as The Cleveland Clinic, Mount Sinai, Mass General, and University of Chicago Medicine, maintaining a dataset exceeding 2.5 million procedures that grows by approximately one million annually. In early 2025, Virgo launched EndoDINO, an AI foundation model trained on over 130,000 procedure videos, excelling in gastrointestinal endoscopy benchmarks and predicting placebo and drug response rates in inflammatory bowel disease from baseline colonoscopy footage. | |
| HQ Country | |||||
| HQ City | San Francisco, CA | San Jose, CA | Louisville, KY | San Diego, CA | |
| Deal Date | 15 Aug 2024 | 15 Jul 2024 | 24 Apr 2023 | 5 Jan 2022 | |
| Round | Series D | Series D | Undisclosed stage | Series A | |
| Raised | $97M | $23M | $15M | $8M | |
| Investors | Olympus; Sonder Capital | Action Potential Venture Capital; Olympus; Treo Ventures; Vertex Ventures HC; Windham Venture Partners | Olympus; Questa Capital Management | American Gastroenterological Association; FCA Venture Partners; Heron Rock Fund; Olympus; Tom Williams | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Olympus investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Olympus
| When was Olympus founded? | Olympus was founded in 1919. |
| Where is Olympus headquartered? | Olympus is headquartered in Japan. |
| How many employees does Olympus have? | As of today, Olympus has over 30K employees. |
| Who is the CEO of Olympus? | Olympus' CEO is Robert Jon White. |
| Is Olympus publicly listed? | Yes, Olympus is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Olympus? | Olympus trades under 7733 ticker. |
| When did Olympus go public? | Olympus went public in 1949. |
| Who are competitors of Olympus? | Olympus main competitors include Smith & Nephew, Penumbra, Medpace, Fisher & Paykel, Align Technology, Solventum, Cooper Companies, Fresenius Medical Care, Zydus Lifesciences, Coloplast. |
| What is the current market cap of Olympus? | Olympus' current market cap is $12B. |
| What is the current revenue of Olympus? | Olympus' last 12 months revenue is $6B. |
| What is the current revenue growth of Olympus? | Olympus revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Olympus? | Current revenue multiple of Olympus is 2.0x. |
| What is the current EBITDA of Olympus? | Olympus' last 12 months EBITDA is $1B. |
| What is Olympus' EBITDA margin? | Olympus' last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Olympus? | Current EBITDA multiple of Olympus is 11.2x. |
| What is the current FCF of Olympus? | Olympus' last 12 months FCF is $148M. |
| What is Olympus' FCF margin? | Olympus' last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of Olympus? | Current FCF multiple of Olympus is 85.4x. |
| How many companies Olympus has acquired to date? | As of June 2026, Olympus has acquired 10 companies. |
| What was the largest acquisition by Olympus? | $370M acquisition of TaeWoong Medical USA on 24th January 2024 was the largest M&A Olympus has done to date. |
| What companies Olympus acquired? | Olympus acquired TaeWoong Medical USA, Taewoong Medical, Veran Medical Technologies, iTind, BioProtect, Image Stream Medical, Odin Vision, Quest Innovations, FH ORTHO SAS, and Arc Medical Design. |
| In how many companies Olympus has invested to date? | As of June 2026, Olympus has invested in 5 companies. |
| What was the last Olympus investment? | On 15th August 2024 Olympus invested in Neptune Medical, participating in a $97M Series D round, alongside Sonder Capital. |
| In what companies Olympus invested in? | Olympus invested in Neptune Medical, LPIXEL, NeuSpera Medical, Eximis Surgical, and Virgo. |
See public comps similar to Olympus
Lists including Olympus
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.



